These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26729247)

  • 21. Macrophage Inhibitory Factor-1 (MIF-1) controls the plasticity of multiple myeloma tumor cells.
    Joseph D; Gonsky JP; Blain SW
    PLoS One; 2018; 13(11):e0206368. PubMed ID: 30383785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination.
    Akhmetzyanova I; McCarron MJ; Parekh S; Chesi M; Bergsagel PL; Fooksman DR
    Leukemia; 2020 Jan; 34(1):245-256. PubMed ID: 31439945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway.
    Wu D; Guo X; Su J; Chen R; Berenzon D; Guthold M; Bonin K; Zhao W; Zhou X
    Biochim Biophys Acta; 2015 Feb; 1853(2):338-47. PubMed ID: 25450979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Detection of circulating and bone marrow myeloma cells in patients with multiple myeloma and its clinical significance].
    Jiang YQ; Li JY; Wu YJ; Yang H; Shen YF; Chen LJ; Xu W; Qian SX; Wu HX; Lu H; Shen RL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct; 14(5):908-12. PubMed ID: 17096887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.
    Bolomsky A; Hose D; Schreder M; Seckinger A; Lipp S; Klein B; Heintel D; Ludwig H; Zojer N
    J Hematol Oncol; 2015 Feb; 8():10. PubMed ID: 25887188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
    Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
    Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.
    Pojero F; Flores-Montero J; Sanoja L; Pérez JJ; Puig N; Paiva B; Bottcher S; van Dongen JJ; Orfao A;
    Cytometry B Clin Cytom; 2016 Jan; 90(1):91-100. PubMed ID: 26130131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple myeloma with CD138 changed from positive to negative: A case report.
    Yu J; Tan L; Wu Q; Rao Y; Ao J; Yang W; Zou B; Chen J
    Cytometry B Clin Cytom; 2021 Mar; 100(2):249-253. PubMed ID: 31967404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial.
    Huhn S; Weinhold N; Nickel J; Pritsch M; Hielscher T; Hummel M; Bertsch U; Huegle-Doerr B; Vogel M; Angermund R; Hänel M; Salwender HJ; Weisel K; Dürig J; Görner M; Kirchner H; Peter N; Graeven U; Lordick F; Hoffmann M; Reimer P; Blau IW; Jauch A; Dembowsky K; Möhler T; Wuchter P; Goldschmidt H
    Bone Marrow Transplant; 2017 Aug; 52(8):1194-1198. PubMed ID: 28504661
    [No Abstract]   [Full Text] [Related]  

  • 31. Circulating Tumour DNA for Detecting Minimal Residual Disease in Multiple Myeloma.
    Pugh TJ
    Semin Hematol; 2018 Jan; 55(1):38-40. PubMed ID: 29759151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells.
    Colla S; Storti P; Donofrio G; Todoerti K; Bolzoni M; Lazzaretti M; Abeltino M; Ippolito L; Neri A; Ribatti D; Rizzoli V; Martella E; Giuliani N
    Leukemia; 2010 Nov; 24(11):1967-70. PubMed ID: 20811474
    [No Abstract]   [Full Text] [Related]  

  • 33. Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders.
    Foulk B; Schaffer M; Gross S; Rao C; Smirnov D; Connelly MC; Chaturvedi S; Reddy M; Brittingham G; Mata M; Repollet M; Rojas C; Auclair D; DeRome M; ; Weiss B; Sasser AK
    Br J Haematol; 2018 Jan; 180(1):71-81. PubMed ID: 29105742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
    Ak I; Gulbas Z
    Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
    Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
    Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stimulus-Responsive Microfluidic Interface Enables Efficient Enrichment and Cytogenetic Profiling of Circulating Myeloma Cells.
    Liu Y; Su R; Song J; Yu X; Lin S; Zhu Z; Yang Y; Zhang M; Yang L; Zhang H; Xu X; Yang C
    ACS Appl Mater Interfaces; 2021 Apr; 13(13):14920-14927. PubMed ID: 33755428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
    Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
    Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
    Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
    Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metastatic hepatocellular carcinoma with CD138 positivity: an unusual mimic of multiple myeloma?
    Ramalingam P; Adeagbo B; Bollag R; Lee J; Reid-Nicholson M
    Diagn Cytopathol; 2008 Oct; 36(10):742-8. PubMed ID: 18773447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients.
    Kuranda K; Berthon C; Dupont C; Wolowiec D; Leleu X; Polakowska R; Jouy N; Quesnel B
    Exp Hematol; 2010 Feb; 38(2):124-31. PubMed ID: 19948206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.